Andrew Liss
Asssitant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (45)
Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMNs) are pancreatic ductal adenocarcinoma (PDAC) precursor lesions. Detecting these precursors and monitoring their progression are crucial for early PDAC diagnosis. Digital PCR (dPCR) is a highly sensitive nucleic acid quantification technique and offers a cost‐effective option for patient follow‐up. However, the clinical utility of conventional dPCR is restricted by multiplexing constraints, particularly due to the challenge of simultaneously quantifying multiple mutations and amplifications. In this study, we applied highly multiplexed dPCR and melting curve analysis to simultaneously measure single nucleotide mutations and amplifications of KRAS and GNAS . The developed 14‐plex assay included both wild‐type and mutant KRAS , a common driver gene in both PanIN and IPMN, and GNAS , which is specifically mutated in IPMN, along with RPP30 , a reference gene for copy number alterations (CNAs). This multiplex dPCR method detected all target mutations with a limit of detection below 0.2% while quantifying CNAs. Additionally, the assay accurately quantified variant allele frequencies in liquid biopsy and tissue samples from both pancreatic neoplasm precursor and PDAC patients, indicating its potential for use in comprehensive patient follow‐up.
Year:
2025
The biliary tree is susceptible to inflammatory injury that can result in severe liver damage. However, the intrapancreatic biliary duct system is largely refractory to damage caused by pancreatitis; the mechanisms that protect these ducts from injury remain unknown. Here, we demonstrate that, although serine/threonine‐protein kinase DCLK1 (DCLK1) + tuft cells and mucin‐2 (MUC2) + goblet cells were largely restricted to the ampulla of non‐injured mice, they exhibited a marked increase in the ampulla and a progressive appearance in the intrapancreatic biliary duct system after injury. The increase in goblet cells was transient and induced upon successive incidence of injury. In contrast, tuft cells persisted in the ductal system and transiently expressed proopiomelanocortin after injury. Mice lacking this tuft and goblet cell response exhibited fibrotic scarring of the ducts and diminished cholangiocyte regeneration. Lineage tracing demonstrated that tuft and goblet cells in the intrapancreatic biliary duct system do not originate from acinar cells, suggesting that tuft cells in the intrapancreatic duct system are derived from a unique progenitor cell, separate from those found in the pancreatic parenchyma after injury. Similar to tuft and goblet cells derived from neighboring leucine‐rich repeat‐containing G‐protein coupled receptor 5 (Lgr5) + stem cells in the small intestine, levels of tuft cells in the ampulla and intrapancreatic biliary ducts are dependent on the activity of the bromodomain and extra‐terminal domain (BET) family of chromatin adaptors, and the hyperplastic response of both tuft and goblet cells requires interleukin‐4 receptor subunit alpha (IL4RA) signaling. Taken together, our results demonstrate a role for tuft and goblet cells in the acute and long‐term monitoring of the intrapancreatic biliary duct system.
Year:
2025
Collagen XVII expression is upregulated in PDAC cells upon interaction with CAFs. A, Western blot analysis of collagen XVII expression in immortalized human pancreatic ductal cells [human pancreatic duct epithelial (HPDE)], six PDAC cell lines, and telomerase reverse transcriptase–immortalized CAFs (CAF-1). β-Actin is shown as a loading control. B, COL17A1 expression in cell lines and matching xenograft tumors. C, Representative IHC staining of collagen XVII in cell line xenografts and PDXs of MGH1319. Scale bars, 50 μm. D, Schematic of the experimental setup of coculture and FACS of PDAC and CAF-1 cells. E, Collagen XVII expression in MGH1319 cells in monoculture and after coculture with CAF-1. β-Actin is shown as a loading control. F–H, Relative COL17A1 expression in MGH1319, MGH1275, MGH1108, and CAF-1 after mono- and coculture. The average (±SEM) from three independent experiments is shown. *, P P t test).
Year:
2025
Pancreatic ductal adenocarcinoma (PDAC) is a highly chemoresistant malignancy with a dismal 11% 5-year survival rate. PDAC tumors are composed of a dense desmoplastic stroma, and the interaction of this collagen-rich tumor microenvironment with PDAC cells promotes their aggressive growth and metastatic spread. In this study, we investigated the role of collagen XVII, a unique transmembrane collagen that connects the extracellular matrix to cytoplasmic signaling complexes. Examination of PDAC tumors revealed that its expression is an independent prognostic biomarker associated with worsened oncological outcomes. Xenograft tumor studies and in vitro coculture experiments with PDAC cell lines and immortalized cancer-associated fibroblasts defined a critical role for the tumor microenvironment in mediating the expression of collagen XVII in the cancer compartment of PDAC tumors. Genetic depletion of collagen XVII reduces the viability and migration of PDAC cells in vitro and orthotopic tumor formation in vivo , underscoring its critical role in PDAC tumor biology. Tumors formed by collagen XVII–depleted PDAC cells exhibit a dramatic downregulation of phosphoinositide 3-kinase regulatory subunit 5, a regulatory subunit of the class I phosphatidylinositol 3-kinase (PI3K) γ complex, and decreased levels of downstream activated AKT. Taken together, these findings reveal collagen XVII signaling as a novel target for PDAC treatment and provide insight into the mechanisms by which it regulates PI3K activity. Significance: Our study highlights the importance of cross-talk between the tumor microenvironment and PDAC cells in mediating the expression of a key signaling pathway responsible for PI3K activity in PDAC cells.
Year:
2025
Collagen XVII is expressed in the cancer cells of PDAC tumors and is associated with poor survival. A, Analysis of COL17A1 expression in cancer vs. normal tissues adapted from Oncomine. The numbers in the graphic indicate the number of datasets, grouped by cancer type, showing statistically significant changes in COL17A1 gene expression between cancer and normal tissues. Significance was defined using the following thresholds: P value ≤ 0.05, fold change ≥2, and inclusion in the top 10% of gene expression rankings. Upregulated gene expression is indicated by red cells, and downregulated gene expression is indicated by blue cells. Cell color intensity reflects the best gene rank percentile across all analyses included in the cell. B, COL17A1 expression of laser capture microdissected (LCM) separated matched cancer and stroma from tumors of patients with PDAC. Each bar represents the ratio of COL17A1 expression in a patient sample in cancer compared with the stroma (E/S, epithelial/stroma). C, Uniform Manifold Approximation and Projection for Dimension Reduction visualization of single cells from normal pancreas, pancreatitis, and PDAC samples. D, COL17A1 expression (purple) in each cell type in the global Uniform Manifold Approximation and Projection for Dimension Reduction. E, Bubble plot demonstrating the expression of transmembrane collagens across cell types. The intensity of the color is proportional to the average expression of the gene within a cluster, and the bubble size is proportional to the number of cells expressing the marker. F, IHC staining of collagen XVII on skin and acinar cells, ducts, and islets in the normal pancreas. Scale bars, 50 μm. G, IHC staining of collagen XVII on PDAC tissue. Representative images show negative, weak, moderate, and strong collagen XVII expression. Scale bars, 100 and 25 µm (inset). H, H -score distribution of collagen XVII expression in 46 treatment-naïve patients with PDAC. I, Kaplan–Meier survival analysis of treatment-naïve patients with PDAC for collagen XVII high ( H -score >130; n = 24) vs. low ( H -score n = 22) expressing PDAC tumors ( n = 46, log-rank test, P = 0.02). J, Kaplan–Meier survival analysis of patients with PDAC for COL17A1 high (FPKM >43.77; n = 64) vs. low (FPKM ≤43.77; n = 112) expressing PDAC tumors ( n = 176, log-rank test, P
Year:
2025
The expression of PIK3R5 and activation of AKT is dependent on collagen XVII. A, Bubble plots illustrating two upregulated gene ontology programs in collagen XVII–deficient MGH1275 cells. B, Volcano plot showing DEGs in tumors formed by MGH1275 cells expressing an NTC vector vs. COL17A1 -specific shRNAs. C, Relative expression of PIK3R5 in tumors formed by MGH1319 cells expressing an NTC shRNA and COL17A1 -specific shRNAs. The mean (±SEM) from three tumors analyzed in triplicate is shown. ***, P post hoc test. D, IHC staining of PIK3R5, P-AKT, and total AKT on orthotopic tumors formed by MGH1319 and MGH1275 cells expressing an NTC vector or COL17A1 -specific shRNAs. Scale bars, 100 and 25 µm (inset). FDR q value, Fasle Discovery Rate-adjusted q -value; NES, normalized enrichment scale; NOM_ P value, nominal P -value.
Year:
2025
Hemidesmosome components integrin β4, integrin α6, and laminin-5 are not correlated with survival in patients with PDAC. A, Representative images of IHC staining of integrin β4, integrin α6, and laminin-5 in normal pancreas and PDAC tissues from 46 treatment-naïve patients with PDAC. Scale bars, 100 and 25 µm (inset). B, H -score distribution of integrin β4 expression. C, Distribution of integrin α6 expression scores ranging from 1 to 3. D, Percentage of PDAC samples positive and negative for laminin-5. E, Kaplan–Meier survival analysis of high ( H -score >131; n = 24) vs. low ( H -score n = 22) integrin β4–expressing patients with PDAC. F, Kaplan–Meier survival analysis of high (score >2; n = 14) vs. low (score ≤2; n = 32) integrin α6–expressing patients with PDAC. G, Kaplan–Meier survival analysis of positive ( n = 19) vs. negative ( n = 27) laminin-5–expressing patients with PDAC.
Year:
2025
Reduced tumor forming potential of COL17A1 -deficient PDAC cells. A, Schematic of orthotopic implantations of PDAC cells into the pancreata of NSG mice and photographs of orthotopic tumors formed by MGH1319 and MGH1275 cells expressing NTC and COL17A1 -specific shRNAs. Scale bars, 1 cm. B and C, MGH1319 expressing NTC and COL17A1 -specific shRNAs were implanted into the pancreas of mice. Tumor volumes were calculated by caliper measurement ( B ), and mass was determined ( C ). Data are presented as mean (±SEM) from five mice per group. **, P P P post hoc test). D, Representative images of collagen XVII IHC (top) and hematoxylin and eosin (H&E) staining (bottom). Scale bars, 50 µm. E and F, MGH1275 cells expressing NTC and COL17A1 -specific shRNAs were implanted into the pancreas of mice. Tumor volumes were calculated by caliper measurement ( E ) and mass determined ( F ). Data are presented as mean (±SEM) from five mice per group. ****, P post hoc test). G, Representative images of collagen XVII IHC (top) and H&E staining (bottom). Scale bars, 50 µm. H, IHC staining of pan-cytokeratin (red) and Ki-67 (brown). I and J, Percentage of Ki-67–positive cancer cells in tumors formed by MGH1319 cells ( I ) and MGH1275 cells ( J ) expressing NTC and COL17A1 -specific shRNAs. The average (±SEM) from four tumors is shown. ***, P P post hoc test).
Year:
2025
Viability and metastatic potential of PDAC cells is dependent on collagen XVII. A, Western blot analysis of collagen XVII in MGH1319, MGH1275, and MGH1108 cells expressing an NTC shRNA and COL17A1 -specific shRNAs. The expression of β-actin served as a control. B, Resazurin-based cell viability assays were performed using MGH1319, MGH1275, and MGH1108 cells expressing NTC and COL17A1 -specific shRNAs. The mean (±SEM) cell viability relative to NTC-expressing cells of three independent experiments performed in triplicate is shown. ***, P post hoc test). C, Representative scratch areas at 0 and 24 hours of MGH1319, MGH1275, and MGH1108 cells expressing NTC and COL17A1 -specific shRNAs. D, The mean (±SEM) scratch closure area relative to 0 hours from three independent biological experiments is shown for MGH1319, MGH1275, and MGH1108. ***, P P post hoc test). E, The mean (±SEM) migration of MGH1319 cells expressing COL17A1 -specific shRNAs relative to cells expressing NTC, as measured by a transwell migration assay. Three independent infections of MGH1319 are shown. *, P P post hoc test). F, Representative images of COX IV IHC staining of lungs harvested from mice 4 weeks after injection with MGH1319 cells expressing an NTC vector or COL17A1 -specific shRNAs. Scale bars, 100 µm. G, Percentage of COX IV–positive area (±SEM) in the lungs of mice with metastasis formed by MGH1319 cells expressing either an NTC or COL17A1 -specific shRNAs ( n = 6 for each shRNA). ****, P post hoc test).
Year:
2025
Distinct fibroblast populations are associated with tissue types. A, UMAP projection based on the top five PCs of fibroblast single-cell transcriptomes. B, UMAP projections of single cells from each tissue type (colored) contributing to the fibroblast UMAP (gray). C, UMAP projections of single cells from autoimmune (left) and idiopathic (right) chronic pancreatitis samples (colored) contributing to the fibroblast UMAP (gray). D, Quantification of each fibroblast cluster within tissue types. E, Bubble plot demonstrating relative expression of marker genes across clusters. The intensity of the color is proportional to the average expression of the marker within a cluster, and the bubble size is proportional to the number of cells expressing the marker. F, Violin plots of the expression of genes with defined roles in fibroblast biology. G, Visualization of selected KEGG and Reactome pathways significantly enriched in fibroblast clusters. The bubble size is proportional to the number of genes enriched, and the intensity of the color is proportional to significance of the enrichment. Normal fibroblasts (F1); inflammatory fibroblasts (F2); injury-reactive fibroblasts (F3); transitional fibroblasts (F4); CAFs (F5). UMAP, UMAP, Uniform Manifold Approximation and Projection for Dimension Reduction.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (30)
Russell Jenkins
Associate Professor
Medical University of South Carolina
Filippo Birocchi
Harvard University
Rajiv McCoy
Associate Professor
Johns Hopkins University
Cristina Ferrone
Chair
Cedars-Sinai Medical Center
Fritz Sedlazeck
Associate Professor
Baylor College of Medicine
Thomas Hank
Attending
University Hospital Heidelberg
Heer Mehta
Assistant Professor
Baylor College of Medicine
Iris Yuwen Zhou
Assistant Professor
Massachusetts General Hospital
Justin Zook
National Institute of Standards and Technology
Jacquelyn W. Zimmerman
Johns Hopkins University School of Medicine
Genevieve Boland
Chair of Surgery
Medical College of Wisconsin
Kenzui Taniue
The Univeristy of Tokyo
Mari Mino-Kenudson
Pathologist
Massachusetts General Hospital
Hua-Jun He
National Institute of Standards and Technology
Motaz Qadan
Hepatobiliary and Pancreatic Surgical Oncologist
Massachusetts General Hospital
Kasper Lage
Group Leader
Broad Institute
Gail L Rosen
College of Engineering
Nathanael Olson
National Institute of Standards and Technology
David Ting
Associate Professor of Medicine
-
Jennifer McDaniel
National Institute of Standards and Technology
Tyler Laszewski
Senior Scientist
Novartis Institutes for BioMedical Research Inc
PD Dr. med. Kim C. Honselmann
Assistant Professor of Surgery
Universitätsklinikum Schleswig-Holstein Campus Kiel
Yusuke Mizukami
Professor
Asahikawa Medical University
Elizabeth M. Jaffee
Johns Hopkins University School of Medicine
Taisuke Baba
Assistant Prof
Nagoya University
Heiko Horn
European Bioinformatics Institute
Richard A. Burkhart
Johns Hopkins University School of Medicine
Zhiyong He
National Institute of Standards and Technology
Peter Caravan
Associate Professor
Massachusetts General Hospital
Todd Armstrong
Johns Hopkins University
Make your next move.
Prepare your application
Review drafts before you send them.